PRECAUTIONS O
General O
Excessive O
diuresis B-NonOSE_AE
may O
cause O
dehydration B-OSE_Labeled_AE
and O
blood B-OSE_Labeled_AE
volume I-OSE_Labeled_AE
reduction I-OSE_Labeled_AE
with O
circulatory B-OSE_Labeled_AE
collapse I-OSE_Labeled_AE
and O
possibly O
vascular B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
embolism O
, O
particularly O
in O
elderly O
patients O
. O

As O
with O
any O
effective O
diuretic B-NonOSE_AE
, O
electrolyte B-OSE_Labeled_AE
depletion I-OSE_Labeled_AE
may O
occur O
during O
furosemide O
therapy O
, O
especially O
in O
patients O
receiving O
higher O
doses O
and O
a O
restricted O
salt O
intake O
. O

Hypokalemia B-OSE_Labeled_AE
may O
develop O
with O
furosemide O
, O
especially O
with O
brisk O
diuresis B-NonOSE_AE
, O
inadequate O
oral O
electrolyte O
intake O
, O
when O
cirrhosis B-Not_AE_Candidate
is O
present O
, O
or O
during O
concomitant O
use O
of O
corticosteroids O
, O
ACTH O
, O
licorice O
in O
large O
amounts O
, O
or O
prolonged O
use O
of O
laxatives O
. O

Digitalis O
therapy O
may O
exaggerate O
metabolic O
effects O
of O
hypokalemia B-NonOSE_AE
, O
especially O
myocardial B-NonOSE_AE
effects I-NonOSE_AE
. O

All O
patients O
receiving O
furosemide O
therapy O
should O
be O
observed O
for O
these O
signs O
or O
symptoms O
of O
fluid B-NonOSE_AE
or O
electrolyte O
imbalance I-NonOSE_AE
( O
hyponatremia B-NonOSE_AE
, O
hypochloremic B-NonOSE_AE
alkalosis I-NonOSE_AE
, O
hypokalemia B-NonOSE_AE
, O
hypomagnesemia B-NonOSE_AE
or O
hypocalcemia B-NonOSE_AE
) O
: O
dryness B-NonOSE_AE
of I-NonOSE_AE
mouth I-NonOSE_AE
, O
thirst B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
drowsiness B-NonOSE_AE
, O
restlessness B-NonOSE_AE
, O
muscle B-NonOSE_AE
pains I-NonOSE_AE
or O
cramps O
, O
muscular B-NonOSE_AE
fatigue I-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
oliguria B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
arrhythmia B-NonOSE_AE
, O
or O
gastrointestinal B-NonOSE_AE
disturbances I-NonOSE_AE
such O
as O
nausea B-NonOSE_AE
and O
vomiting B-NonOSE_AE
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
and O
alterations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
tolerance I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
with O
abnormalities B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
and O
2-hour O
postprandial O
sugar I-OSE_Labeled_AE
) O
have O
been O
observed O
, O
and O
rarely O
, O
precipitation O
of O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
has O
been O
reported O
. O

In O
patients O
with O
severe O
symptoms O
of O
urinary B-Not_AE_Candidate
retention I-Not_AE_Candidate
( O
because O
of O
bladder B-Not_AE_Candidate
emptying I-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
prostatic B-Not_AE_Candidate
hyperplasia I-Not_AE_Candidate
, O
urethral B-Not_AE_Candidate
narrowing I-Not_AE_Candidate
) O
, O
the O
administration O
of O
furosemide O
can O
cause O
acute B-OSE_Labeled_AE
urinary I-OSE_Labeled_AE
retention I-OSE_Labeled_AE
related O
to O
increased B-NonOSE_AE
production I-NonOSE_AE
and O
retention O
of I-NonOSE_AE
urine I-NonOSE_AE
. O

Thus O
, O
these O
patients O
require O
careful O
monitoring O
, O
especially O
during O
the O
initial O
stages O
of O
treatment O
. O

In O
patients O
at O
high O
risk O
for O
radiocontrast B-Not_AE_Candidate
nephropathy I-Not_AE_Candidate
furosemide O
can O
lead O
to O
a O
higher O
incidence O
of O
deterioration B-NonOSE_AE
in I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
after O
receiving O
radiocontrast O
compared O
to O
high-risk O
patients O
who O
received O
only O
intravenous O
hydration O
prior O
to O
receiving O
radiocontrast O
. O

In O
patients O
with O
hypoproteinemia B-Not_AE_Candidate
( O
e.g. O
, O
associated O
with O
nephrotic B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
) O
the O
effect O
of O
furosemide O
may O
be O
weakened O
and O
its O
ototoxicity B-OSE_Labeled_AE
potentiated O
. O

Asymptomatic O
hyperuricemia B-OSE_Labeled_AE
can O
occur O
and O
gout B-OSE_Labeled_AE
may O
rarely O
be O
precipitated O
. O

Patients O
allergic B-OSE_Labeled_AE
to I-OSE_Labeled_AE
sulfonamides I-OSE_Labeled_AE
may I-OSE_Labeled_AE
also I-OSE_Labeled_AE
be I-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
to I-OSE_Labeled_AE
furosemide I-OSE_Labeled_AE
. O

The O
possibility O
exists O
of O
exacerbation O
or O
activation O
of O
systemic B-OSE_Labeled_AE
lupus I-OSE_Labeled_AE
erythematosus I-OSE_Labeled_AE
. O

As O
with O
many O
other O
drugs O
, O
patients O
should O
be O
observed O
regularly O
for O
the O
possible O
occurrence O
of O
blood B-NonOSE_AE
dyscrasias I-NonOSE_AE
, O
liver B-NonOSE_AE
or O
kidney O
damage I-NonOSE_AE
, O
or O
other O
idiosyncratic B-NonOSE_AE
reactions I-NonOSE_AE
. O

Information O
for O
Patients O
Patients O
receiving O
furosemide O
should O
be O
advised O
that O
they O
may O
experience O
symptoms O
from O
excessive O
fluid B-NonOSE_AE
and/or O
electrolyte O
losses I-NonOSE_AE
. O

The O
postural B-NonOSE_AE
hypotension I-NonOSE_AE
that O
sometimes O
occurs O
can O
usually O
be O
managed O
by O
getting O
up O
slowly O
. O

Potassium O
supplements O
and/or O
dietary O
measures O
may O
be O
needed O
to O
control O
or O
avoid O
hypokalemia B-NonOSE_AE
. O

Patients O
with O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
should O
be O
told O
that O
furosemide O
may O
increase B-NonOSE_AE
blood I-NonOSE_AE
glucose I-NonOSE_AE
levels I-NonOSE_AE
and O
thereby O
affect O
urine O
glucose O
tests O
. O

The O
skin B-NonOSE_AE
of I-NonOSE_AE
some I-NonOSE_AE
patients I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
more I-NonOSE_AE
sensitive I-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
effects I-NonOSE_AE
of I-NonOSE_AE
sunlight I-NonOSE_AE
while O
taking O
furosemide O
. O

Hypertensive B-Not_AE_Candidate
patients O
should O
avoid O
medications O
that O
may O
increase B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
including O
over-the-counter O
products O
for O
appetite B-Not_AE_Candidate
suppression I-Not_AE_Candidate
and O
cold B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
. O

Laboratory O
Tests O
Serum O
electrolytes O
( O
particularly O
potassium O
) O
, O
CO2 O
, O
creatinine O
and O
BUN O
should O
be O
determined O
frequently O
during O
the O
first O
few O
months O
of O
furosemide O
therapy O
and O
periodically O
thereafter O
. O

Serum O
and O
urine O
electrolyte O
determinations O
are O
particularly O
important O
when O
the O
patient O
is O
vomiting B-NonOSE_AE
profusely O
or O
receiving O
parenteral O
fluids O
. O

Abnormalities O
should O
be O
corrected O
or O
the O
drug O
temporarily O
withdrawn O
. O

Other O
medications O
may O
also O
influence O
serum O
electrolytes O
. O

Reversible O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
BUN I-OSE_Labeled_AE
may O
occur O
and O
are O
associated O
with O
dehydration B-OSE_Labeled_AE
, O
which O
should O
be O
avoided O
, O
particularly O
in O
patients O
with O
renal B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
. O

Urine O
and O
blood O
glucose O
should O
be O
checked O
periodically O
in O
diabetics B-Not_AE_Candidate
receiving O
furosemide O
, O
even O
in O
those O
suspected O
of O
latent O
diabetes B-Not_AE_Candidate
. O

Furosemide O
may O
lower B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
( O
rarely O
cases O
of O
tetany B-OSE_Labeled_AE
have O
been O
reported O
) O
and O
magnesium O
. O

Accordingly O
, O
serum O
levels O
of O
these O
electrolytes O
should O
be O
determined O
periodically O
. O

In O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
furosemide O
may O
precipitate O
nephrocalcinosis B-OSE_Labeled_AE
/ O
nephrolithiasis B-OSE_Labeled_AE
, O
therefore O
renal O
function O
must O
be O
monitored O
and O
renal O
ultrasonography O
performed O
. O

( O
See O
PRECAUTIONS O
: O
Pediatric O
Use O
) O
Drug O
Interactions O
Furosemide O
may O
increase O
the O
ototoxic B-NonOSE_AE
potential O
of O
aminoglycoside O
antibiotics O
, O
especially O
in O
the O
presence O
of O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Except O
in O
life-threatening O
situations O
, O
avoid O
this O
combination O
. O

Furosemide O
should O
not O
be O
used O
concomitantly O
with O
ethacrynic O
acid O
because O
of O
the O
possibility O
of O
ototoxicity B-NonOSE_AE
. O

Patients O
receiving O
high O
doses O
of O
salicylates O
concomitantly O
with O
furosemide O
, O
as O
in O
rheumatic O
disease O
, O
may O
experience O
salicylate B-NonOSE_AE
toxicity I-NonOSE_AE
at O
lower O
doses O
because O
of O
competitive O
renal O
excretory O
sites O
. O

There O
is O
a O
risk O
of O
ototoxic B-NonOSE_AE
effects O
if O
cisplatin O
and O
furosemide O
are O
given O
concomitantly O
. O

In O
addition O
, O
nephrotoxicity B-NonOSE_AE
of O
nephrotoxic B-NonOSE_AE
drugs I-NonOSE_AE
such O
as O
cisplatin O
may O
be O
enhanced O
if O
furosemide O
is O
not O
given O
in O
lower O
doses O
and O
with O
positive B-NonOSE_AE
fluid I-NonOSE_AE
balance I-NonOSE_AE
when O
used O
to O
achieve O
forced O
diuresis B-NonOSE_AE
during O
cisplatin O
treatment O
. O

Furosemide O
has O
a O
tendency O
to O
antagonize O
the O
skeletal O
muscle O
relaxing O
effect O
of O
tubocurarine O
and O
may O
potentiate O
the O
action O
of O
succinylcholine O
. O

Lithium O
generally O
should O
not O
be O
given O
with O
diuretics B-NonOSE_AE
because O
they O
reduce O
lithium O
's O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-NonOSE_AE
toxicity I-NonOSE_AE
. O

Furosemide O
combined O
with O
angiotensin O
converting O
enzyme O
inhibitors O
or O
angiotensin O
II O
receptor O
blockers O
may O
lead O
to O
severe O
hypotension B-NonOSE_AE
and O
deterioration B-NonOSE_AE
in I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
, O
including O
renal B-NonOSE_AE
failure I-NonOSE_AE
. O

An O
interruption O
or O
reduction O
in O
the O
dosage O
of O
furosemide O
, O
angiotensin O
converting O
enzyme O
inhibitors O
, O
or O
angiotensin O
receptor O
blockers O
may O
be O
necessary O
. O

Potentiation O
occurs O
with O
ganglionic O
or O
peripheral O
adrenergic O
blocking O
drugs O
. O

Furosemide O
may O
decrease B-NonOSE_AE
arterial I-NonOSE_AE
responsiveness I-NonOSE_AE
to O
norepinephrine O
. O

However O
, O
norepinephrine O
may O
still O
be O
used O
effectively O
. O

Simultaneous O
administration O
of O
sucralfate O
and O
furosemide O
tablets O
may O
reduce B-NonOSE_AE
the I-NonOSE_AE
natriuretic I-NonOSE_AE
and O
antihypertensive O
effects O
of O
furosemide O
. O

Patients O
receiving O
both O
drugs O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic B-NonOSE_AE
and/or O
antihypertensive B-NonOSE_AE
effect I-NonOSE_AE
of O
furosemide O
is O
achieved O
. O

The O
intake O
of O
furosemide O
and O
sucralfate O
should O
be O
separated O
by O
at O
least O
two O
hours O
. O

In O
isolated O
cases O
, O
intravenous O
administration O
of O
furosemide O
within O
24 O
hours O
of O
taking O
chloral O
hydrate O
may O
lead O
to O
flushing B-NonOSE_AE
, O
sweating B-NonOSE_AE
attacks I-NonOSE_AE
, O
restlessness B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
increase B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
and O
tachycardia B-NonOSE_AE
. O

Use O
of O
furosemide O
concomitantly O
with O
chloral O
hydrate O
is O
, O
therefore O
, O
not O
recommended O
. O

Phenytoin O
interferes O
directly O
with O
renal O
action O
of O
furosemide O
. O

There O
is O
evidence O
that O
treatment O
with O
phenytoin O
leads O
to O
decrease O
intestinal O
absorption O
of O
furosemide O
, O
and O
consequently O
to O
lower O
peak O
serum O
furosemide O
concentrations O
. O

Methotrexate O
and O
other O
drugs O
that O
, O
like O
furosemide O
, O
undergo O
significant O
renal O
tubular O
secretion O
may O
reduce O
the O
effect O
of O
furosemide O
. O

Conversely O
, O
furosemide O
may O
decrease O
renal O
elimination O
of O
other O
drugs O
that O
undergo O
tubular O
secretion O
. O

High-dose O
treatment O
of O
both O
furosemide O
and O
these O
other O
drugs O
, O
may O
result O
in O
elevated O
serum O
levels O
of O
these O
drugs O
and O
may O
potentiate O
their O
toxicity O
as O
well O
as O
the O
toxicity B-NonOSE_AE
of I-NonOSE_AE
furosemide I-NonOSE_AE
. O

Furosemide O
can O
increase O
the O
risk O
of O
cephalosporin B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
nephrotoxicity I-NonOSE_AE
even O
in O
the O
setting O
of O
minor O
or O
transient O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Concomitant O
use O
of O
cyclosporine O
and O
furosemide O
is O
associated O
with O
increased O
risk O
of O
gouty B-NonOSE_AE
arthritis I-NonOSE_AE
secondary O
to O
furosemide-induced O
hyperurecemia B-OSE_Labeled_AE
and O
cyclosporine O
impairment B-NonOSE_AE
of I-NonOSE_AE
renal I-NonOSE_AE
urate I-NonOSE_AE
excretion I-NonOSE_AE
. O

High O
doses O
( O
> O
80 O
mg O
) O
of O
furosemide O
may O
inhibit O
the O
binding O
of O
thyroid O
hormones O
to O
carrier O
proteins O
and O
result O
in O
transient O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
free I-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
hormones I-OSE_Labeled_AE
, O
followed O
by O
an O
overall O
decrease B-NonOSE_AE
in I-NonOSE_AE
total I-NonOSE_AE
thyroid I-NonOSE_AE
hormone I-NonOSE_AE
levels I-NonOSE_AE
. O

One O
study O
in O
six O
subjects O
demonstrated O
that O
the O
combination O
of O
furosemide O
and O
acetylsalicylic O
acid O
temporarily O
reduced B-NonOSE_AE
creatinine I-NonOSE_AE
clearance I-NonOSE_AE
in O
patients O
with O
chronic B-Not_AE_Candidate
renal I-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
. O

There O
are O
case O
reports O
of O
patients O
who O
developed O
increased B-NonOSE_AE
BUN I-NonOSE_AE
, O
serum O
creatinine O
and O
serum O
potassium O
levels O
, O
and O
weight B-NonOSE_AE
gain I-NonOSE_AE
when O
furosemide O
was O
used O
in O
conjunction O
with O
NSAIDs O
. O

Literature O
reports O
indicate O
that O
coadministration O
of O
indomethacin O
may O
reduce B-NonOSE_AE
the I-NonOSE_AE
natriuretic I-NonOSE_AE
and O
antihypertensive O
effects I-NonOSE_AE
of O
furosemide O
in O
some O
patients O
by O
inhibiting O
prostaglandin O
synthesis O
. O

Indomethacin O
may O
also O
affect O
plasma O
renin O
levels O
, O
aldosterone O
excretion O
, O
and O
renin O
profile O
evaluation O
. O

Patients O
receiving O
both O
indomethacin O
and O
furosemide O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic B-NonOSE_AE
and/or O
antihypertensive B-NonOSE_AE
effect I-NonOSE_AE
of O
furosemide O
is O
achieved O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
Furosemide O
was O
tested O
for O
carcinogenicity B-NonOSE_AE
by O
oral O
administration O
in O
one O
strain O
of O
mice O
and O
one O
strain O
of O
rats O
. O

A O
small O
but O
significantly O
increased O
incidence O
of O
mammary B-NonOSE_AE
gland I-NonOSE_AE
carcinomas I-NonOSE_AE
occurred O
in O
female O
mice O
at O
a O
dose O
17.5 O
times O
the O
maximum O
human O
dose O
of O
600 O
mg O
. O

There O
were O
marginal O
increases O
in O
uncommon O
tumors B-NonOSE_AE
in O
male O
rats O
at O
a O
dose O
of O
15 O
mg/kg O
( O
slightly O
greater O
than O
the O
maximum O
human O
dose O
) O
but O
not O
at O
30 O
mg/kg O
. O

Furosemide O
was O
devoid O
of O
mutagenic B-NonOSE_AE
activity O
in O
various O
strains O
of O
Salmonella O
typhimurium O
when O
tested O
in O
the O
presence O
or O
absence O
of O
an O
in O
vitro O
metabolic O
activation O
system O
, O
and O
questionably O
positive B-NonOSE_AE
for I-NonOSE_AE
gene I-NonOSE_AE
mutation I-NonOSE_AE
in I-NonOSE_AE
mouse I-NonOSE_AE
lymphoma I-NonOSE_AE
cells I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
presence I-NonOSE_AE
of I-NonOSE_AE
rat I-NonOSE_AE
liver I-NonOSE_AE
S9 O
at O
the O
highest O
dose O
tested O
. O

Furosemide O
did O
not O
induce O
sister B-NonOSE_AE
chromatid I-NonOSE_AE
exchange I-NonOSE_AE
in O
human O
cells O
in O
vitro O
, O
but O
other O
studies O
on O
chromosomal B-NonOSE_AE
aberrations I-NonOSE_AE
in O
human O
cells O
in O
vitro O
gave O
conflicting O
results O
. O

In O
Chinese O
hamster O
cells O
it O
induced O
chromosomal B-NonOSE_AE
damage I-NonOSE_AE
but O
was O
questionably O
positive B-NonOSE_AE
for I-NonOSE_AE
sister I-NonOSE_AE
chromatid I-NonOSE_AE
exchange I-NonOSE_AE
. O

Studies O
on O
the O
induction O
by O
furosemide O
of O
chromosomal B-NonOSE_AE
aberrations I-NonOSE_AE
in O
mice O
were O
inconclusive O
. O

The O
urine O
of O
rats O
treated O
with O
this O
drug O
did O
not O
induce B-NonOSE_AE
gene I-NonOSE_AE
conversion I-NonOSE_AE
in I-NonOSE_AE
Saccharomyces I-NonOSE_AE
cerevisiae I-NonOSE_AE
. O

Furosemide O
produced O
no B-NonOSE_AE
impairment I-NonOSE_AE
of I-NonOSE_AE
fertility I-NonOSE_AE
in O
male O
or O
female O
rats O
, O
at O
100 O
mg/kg/day O
( O
the O
maximum O
effective O
diuretic B-NonOSE_AE
dose O
in O
the O
rat O
and O
8 O
times O
the O
maximal O
human O
dose O
of O
600 O
mg/day O
) O
. O

Pregnancy O
Pregnancy O
Category O
C O
Furosemide O
has O
been O
shown O
to O
cause O
unexplained O
maternal B-NonOSE_AE
deaths I-NonOSE_AE
and O
abortions B-NonOSE_AE
in O
rabbits O
at O
2 O
, O
4 O
and O
8 O
times O
the O
maximal O
recommended O
human O
dose O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

Furosemide O
should O
be O
used O
during O
pregnancy B-Not_AE_Candidate
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
fetus I-NonOSE_AE
. O

Treatment O
during O
pregnancy B-Not_AE_Candidate
requires O
monitoring O
of O
fetal O
growth O
because O
of O
the O
potential O
for O
higher B-OSE_Labeled_AE
birth I-OSE_Labeled_AE
weights I-OSE_Labeled_AE
. O

The O
effects O
of O
furosemide O
on O
embryonic O
and O
fetal O
development O
and O
on O
pregnant B-NonOSE_AE
dams O
were O
studied O
in O
mice O
, O
rats O
and O
rabbits O
. O

Furosemide O
caused O
unexplained O
maternal B-NonOSE_AE
deaths I-NonOSE_AE
and O
abortions B-NonOSE_AE
in O
the O
rabbit O
at O
the O
lowest O
dose O
of O
25 O
mg/kg O
( O
2 O
times O
the O
maximal O
recommended O
human O
dose O
of O
600 O
mg/day O
) O
. O

In O
another O
study O
, O
a O
dose O
of O
50 O
mg/kg O
( O
4 O
times O
the O
maximal O
recommended O
human O
dose O
of O
600 O
mg/day O
) O
also O
caused O
maternal B-NonOSE_AE
deaths I-NonOSE_AE
and O
abortions B-NonOSE_AE
when O
administered O
to O
rabbits O
between O
Days O
12 O
and O
17 O
of O
gestation O
. O

In O
a O
third O
study O
, O
none O
of O
the O
pregnant B-NonOSE_AE
rabbits O
survived O
a O
dose O
of O
100 O
mg/kg O
. O

Data O
from O
the O
above O
studies O
indicate O
fetal B-NonOSE_AE
lethality I-NonOSE_AE
that O
can O
precede O
maternal B-NonOSE_AE
deaths I-NonOSE_AE
. O

The O
results O
of O
the O
mouse O
study O
and O
one O
of O
the O
three O
rabbit O
studies O
also O
showed O
an O
increased O
incidence O
and O
severity O
of O
hydronephrosis B-NonOSE_AE
( O
distention O
of O
the O
renal O
pelvis O
and O
, O
in I-NonOSE_AE
some O
cases O
, O
of O
the O
ureters O
) O
in O
fetuses I-NonOSE_AE
derived O
from O
the O
treated O
dams O
as O
compared O
with O
the O
incidence O
in O
fetuses O
from O
the O
control O
group O
. O

Nursing O
Mothers O
Because O
it O
appears O
in O
breast O
milk O
, O
caution O
should O
be O
exercised O
when O
furosemide O
is O
administered O
to O
a O
nursing O
mother O
. O

Furosemide O
may O
inhibit B-OSE_Labeled_AE
lactation I-OSE_Labeled_AE
. O

Pediatric O
Use O
In O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
furosemide O
may O
precipitate O
nephrocalcinosis B-OSE_Labeled_AE
/ O
nephrolithiasis B-OSE_Labeled_AE
. O

Nephrocalcinosis B-OSE_Labeled_AE
/ O
nephrolithiasis B-OSE_Labeled_AE
has O
also O
been O
observed O
in O
children O
under O
4 O
years O
of O
age O
with O
no O
history O
of O
prematurity B-Not_AE_Candidate
who O
have O
been O
treated O
chronically O
with O
furosemide O
. O

Monitor O
renal O
function O
, O
and O
renal O
ultrasonography O
should O
be O
considered O
, O
in O
pediatric O
patients O
receiving O
furosemide O
. O

If O
furosemide O
is O
administered O
to O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
during O
the O
first O
weeks O
of O
life O
, O
it O
may O
increase O
the O
risk O
of O
persistence O
of O
patent B-OSE_Labeled_AE
ductus I-OSE_Labeled_AE
arteriosus I-OSE_Labeled_AE
. O

Geriatric O
Use O
Controlled O
clinical O
studies O
of O
furosemide O
did O
not O
include O
sufficient O
numbers O
of O
subjects O
aged O
65 O
and O
over O
to O
determine O
whether O
they O
respond O
differently O
from O
younger O
subjects O
. O

Other O
reported O
clinical O
experience O
has O
not O
identified O
differences O
in O
responses O
between O
the O
elderly O
and O
younger O
patients O
. O

In O
general O
, O
dose O
selection O
for O
the O
elderly O
patient O
should O
be O
cautious O
, O
usually O
starting O
at O
the O
low O
end O
of O
the O
dosing O
range O
, O
reflecting O
the O
greater O
frequency O
of O
decreased B-Not_AE_Candidate
hepatic I-Not_AE_Candidate
, O
renal O
or O
cardiac O
function I-Not_AE_Candidate
, O
and O
of O
concomitant O
disease O
or O
other O
drug O
therapy O
. O

This O
drug O
is O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
, O
and O
the O
risk O
of O
toxic B-NonOSE_AE
reactions I-NonOSE_AE
to O
this O
drug O
may O
be O
greater O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
care O
should O
be O
taken O
in O
dose O
selection O
and O
it O
may O
be O
useful O
to O
monitor O
renal O
function O
. O

( O
See O
PRECAUTIONS O
: O
General O
and O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O

